Thomas Sullivan
Medical · Huntingdon, PANPI 1841212032
Payments from drug & device makers
Across 276 payments — averaging $16.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$840
- AbbVie$657
- Lilly USA, LLC$593
- GSK$325
- Astellas Pharma US Inc$220
- AstraZeneca$192
- plus $2K from 32 others
What the payments were for
- Food & beverage$4,42598%
- Education$852%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$4,510 in reported general payments places this provider in the 90th percentile of 2,594 medical providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 62 | $68,256 |
| EliquisApixaban | 67 | $55,840 |
| JardianceEmpagliflozin | 33 | $44,196 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 26 | $33,829 |
| FarxigaDapagliflozin Propanediol | 26 | $27,238 |
| XareltoRivaroxaban | 20 | $26,987 |
| MounjaroTirzepatide | 18 | $22,421 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $21,175 |
| EntrestoSacubitril/Valsartan | 25 | $18,402 |
| TradjentaLinagliptin | 11 | $15,566 |
| TrulicityDulaglutide | 16 | $12,395 |
| RexultiBrexpiprazole | 12 | $11,785 |
| LinzessLinaclotide | 13 | $11,384 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 23 | $10,800 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $6,834 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $840 | $68,25662 claims |
| Boehringer IngelheimJardiance, Tradjenta | $115 | $59,76244 claims |
| PfizerEliquis | $90 | $55,84067 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $325 | $38,80868 claims |
| Lilly USA, LLCMounjaro, Trulicity | $593 | $34,81534 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $102 | $33,82926 claims |
| AstraZenecaFarxiga | $192 | $27,23826 claims |
| Johnson & JohnsonXarelto | $21 | $26,98720 claims |
| NovartisEntresto | $17 | $18,40225 claims |
| AbbVieLinzess, Synthroid | $657 | $12,85143 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $80 | $11,78512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,594 medical providers in Pennsylvania.
Other medical in Huntingdon
- Jacqueline KernaghanSpringfield$427K
- Drew SodaNew Hope$220K
- Angela KapalkoPhiladelphia$123K
- Linda PerryPhiladelphia$123K
- Cory DavidsonErie$119K
- Shelley SassamanTamaqua$90K
- Meghan HoffnerBethlehem$86K
- Thomas IacovoniDanville$72K
- Scott CoxWynnewood$66K
- Sarah SmithPhiladelphia$65K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.